Prolactinoma classification
|
Prolactinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prolactinoma classification On the Web |
|
American Roentgen Ray Society Images of Prolactinoma classification |
|
Risk calculators and risk factors for Prolactinoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Prolactinoma can be classified based upon either size or local invasion. Based on size, a prolactinoma can be classified as a microprolactinoma (<10 mm diameter) or macroprolactinoma (>10 mm diameter).
Classification
Prolactinoma may be classified based on either size or local invasion.
Classification based on size
Based on size, a prolactinoma can be classified as:
- Microprolactinoma (<10 mm diameter)
- Macroprolactinoma (>10 mm diameter)
Classificatioin based on local invasion[1][2][3]
The classification for pituitary adenomas is as follows:
- 0: Normal pituitary appearance
- I: Enclosed within the sella turcica, microadenoma, smaller than 10 mm
- II: Enclosed within the sella turcica, macroadenoma, 10 mm or larger
- III: Invasive, locally, into the sella turcica
- IV: Invasive, diffusely, into the sella turcica
The grading scheme for suprasellar extensions is as follows:
- A: 0 to 10 mm suprasellar extension occupying the suprasellarcistern
- B: 10 mm to 20 mm extension and elevation of the third ventricle
- C: 20 mm to 30 mm extension occupying the anterior of the third ventricle
- D: A larger than 30 mm extension, beyond the foramen of Monro, or Grade C with lateral extensions
References
- ↑ "Pituitary Tumors Treatment (PDQ®)—Health Professional Version - National Cancer Institute".
- ↑ Yeh PJ, Chen JW (1997). "Pituitary tumors: surgical and medical management". Surg Oncol. 6 (2): 67–92. PMID 09436654.
- ↑ Hardy J: Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO, Ross GT, eds.: Diagnosis and treatment of pituitary tumors: proceedings of a conference sponsored jointly by the National Institute of Child Health and Human Development and the National Cancer Institute, January 15-17, 1973, Bethesda, Md. Amsterdam, The Netherlands: Excerpta medica, 1973, pp 179-98